Nortem Biogroup (XPAR:MLBIO) Debt-to-Equity : 0.96 (As of Dec. 2022)

View and export this data going back to 2023. Start your Free Trial

What is Nortem Biogroup Debt-to-Equity?

Nortem Biogroup's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was €2.98 Mil. Nortem Biogroup's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was €3.39 Mil. Nortem Biogroup's Total Stockholders Equity for the quarter that ended in Dec. 2022 was €6.62 Mil. Nortem Biogroup's debt to equity for the quarter that ended in Dec. 2022 was 0.96.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Nortem Biogroup's Debt-to-Equity or its related term are showing as below:

XPAR:MLBIO' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.75 Med: 0.86 Max: 0.96
Current: 0.96

During the past 2 years, the highest Debt-to-Equity Ratio of Nortem Biogroup was 0.96. The lowest was 0.75. And the median was 0.86.

XPAR:MLBIO's Debt-to-Equity is not ranked
in the Consumer Packaged Goods industry.
Industry Median: 0.4 vs XPAR:MLBIO: 0.96

Nortem Biogroup Debt-to-Equity Historical Data

The historical data trend for Nortem Biogroup's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nortem Biogroup Debt-to-Equity Chart

Nortem Biogroup Annual Data

Trend

Dec21

Dec22

Debt-to-Equity

0.75

0.96

Nortem Biogroup Semi-Annual Data
	Dec21	Dec22
Debt-to-Equity	0.75	0.96

Competitive Comparison of Nortem Biogroup's Debt-to-Equity

For the Packaged Foods subindustry, Nortem Biogroup's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nortem Biogroup's Debt-to-Equity Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Nortem Biogroup's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Nortem Biogroup's Debt-to-Equity falls into.

Nortem Biogroup Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Nortem Biogroup's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.976	+	3.385)	/	6.616
	=	0.96

Nortem Biogroup's Debt to Equity Ratio for the quarter that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.976	+	3.385)	/	6.616
	=	0.96

Nortem Biogroup (XPAR:MLBIO) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Nortem Biogroup Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Nortem Biogroup's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Nortem Biogroup (XPAR:MLBIO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Nortem Biogroup (XPAR:MLBIO) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Calle Alexander Humboldt 12B, Polígono Industrial Salinas de Poniente, El Puerto de Santa María, Cadiz, ESP, 11500

Website

https://www.nortembiogroup.com

Nortem Chem SA is engaged in the research, development, innovation and industrialization in the field of biochemistry and biotechnology, as well as the production and sale of products based on biochemical and/or biotechnological processes. It emerged as a biotechnological company in the field of the food and chemical industry, with maximum environmental awareness, concentrating its research and product development efforts on the development of environmentally friendly alternatives from renewable sources and obtaining its own microorganisms (Aspergillus Niger and Yarrowia lipolytica) with outstanding capabilities from adaptation and selection processes, avoiding the use of genetic modification technologies.

Nortem Biogroup (XPAR:MLBIO) Headlines

No Headlines